Cover Image
市場調查報告書

Santhera Pharmaceuticals Holding AG- 產品平台檢討

Santhera Pharmaceuticals Holding AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251767
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Santhera Pharmaceuticals Holding AG- 產品平台檢討 Santhera Pharmaceuticals Holding AG - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 34 Pages
簡介

Santhera Pharmaceuticals Holding AG是總公司設立於瑞士的製藥企業。主要從事神經肌肉疾病及粒腺體性疾病新治療藥之開發及商品化。Leber遺傳性視神經病變的治療藥候補Catena/Raxone受到法國暫時性認証。

本報告提供Santhera Pharmaceuticals Holding AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Santhera Pharmaceuticals Holding AG的基本資料

  • Santhera Pharmaceuticals Holding AG概要
  • 主要資訊
  • 企業資料

Santhera Pharmaceuticals Holding AG:R&D概要

  • 主要的治療範圍

Santhera Pharmaceuticals Holding AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Santhera Pharmaceuticals Holding AG:開發中產品概況

  • 後期階段產品開發中產品
    • 登記前階段的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式

Santhera Pharmaceuticals Holding AG:藥物簡介

  • idebenone
  • fipamezole
  • omigapil

Santhera Pharmaceuticals Holding AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Santhera Pharmaceuticals Holding AG:最近的開發平台資訊

Santhera Pharmaceuticals Holding AG:開發暫停中的計劃

Santhera Pharmaceuticals Holding AG:開發中止的開發中產品

開發中止的開發中產品簡介

Santhera Pharmaceuticals Holding AG:企業理念

Santhera Pharmaceuticals Holding AG:總公司和子公司的所在地

  • 總公司
  • 子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07136CDB

Summary

Global Markets Direct's, 'Santhera Pharmaceuticals Holding AG - Product Pipeline Review - 2015', provides an overview of the Santhera Pharmaceuticals Holding AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Santhera Pharmaceuticals Holding AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Santhera Pharmaceuticals Holding AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Santhera Pharmaceuticals Holding AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Santhera Pharmaceuticals Holding AG's pipeline products

Reasons to buy

  • Evaluate Santhera Pharmaceuticals Holding AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Santhera Pharmaceuticals Holding AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Santhera Pharmaceuticals Holding AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Santhera Pharmaceuticals Holding AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santhera Pharmaceuticals Holding AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Santhera Pharmaceuticals Holding AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Santhera Pharmaceuticals Holding AG Snapshot
    • Santhera Pharmaceuticals Holding AG Overview
    • Key Information
    • Key Facts
  • Santhera Pharmaceuticals Holding AG - Research and Development Overview
    • Key Therapeutic Areas
  • Santhera Pharmaceuticals Holding AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Santhera Pharmaceuticals Holding AG - Pipeline Products Glance
    • Santhera Pharmaceuticals Holding AG - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Santhera Pharmaceuticals Holding AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Santhera Pharmaceuticals Holding AG - Drug Profiles
    • idebenone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fipamezole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omigapil
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Santhera Pharmaceuticals Holding AG - Pipeline Analysis
    • Santhera Pharmaceuticals Holding AG - Pipeline Products by Target
    • Santhera Pharmaceuticals Holding AG - Pipeline Products by Route of Administration
    • Santhera Pharmaceuticals Holding AG - Pipeline Products by Molecule Type
    • Santhera Pharmaceuticals Holding AG - Pipeline Products by Mechanism of Action
  • Santhera Pharmaceuticals Holding AG - Recent Pipeline Updates
  • Santhera Pharmaceuticals Holding AG - Dormant Projects
  • Santhera Pharmaceuticals Holding AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • idebenone
      • omigapil
  • Santhera Pharmaceuticals Holding AG - Company Statement
  • Santhera Pharmaceuticals Holding AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Santhera Pharmaceuticals Holding AG, Key Information
  • Santhera Pharmaceuticals Holding AG, Key Facts
  • Santhera Pharmaceuticals Holding AG - Pipeline by Indication, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Stage of Development, 2015
  • Santhera Pharmaceuticals Holding AG - Monotherapy Products in Pipeline, 2015
  • Santhera Pharmaceuticals Holding AG - Pre-Registration, 2015
  • Santhera Pharmaceuticals Holding AG - Phase III, 2015
  • Santhera Pharmaceuticals Holding AG - Phase II, 2015
  • Santhera Pharmaceuticals Holding AG - Phase I, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Target, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Route of Administration, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Molecule Type, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline Products by Mechanism of Action, 2015
  • Santhera Pharmaceuticals Holding AG - Recent Pipeline Updates, 2015
  • Santhera Pharmaceuticals Holding AG - Dormant Developmental Projects,2015
  • Santhera Pharmaceuticals Holding AG - Discontinued Pipeline Products, 2015
  • Santhera Pharmaceuticals Holding AG, Subsidiaries

List of Figures

  • Santhera Pharmaceuticals Holding AG - Pipeline by Top 10 Indication, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Stage of Development, 2015
  • Santhera Pharmaceuticals Holding AG - Monotherapy Products in Pipeline, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Top 10 Target, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Top 10 Route of Administration, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline by Top 10 Molecule Type, 2015
  • Santhera Pharmaceuticals Holding AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top